Skip to main content

Mosaic ImmunoEngineering Inc

For the period ended Dec 31, 2023. Filed Apr 15, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 15, 2024

CPMVStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

Year Ended December 31, 2023Year Ended December 31, 2022
Operating activities:
Net loss$(1,008,235)$(2,380,870)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation21,935295,123
Gain on redemption of preferred stock of Holocom(433,000)(343,000)
Change in fair value of derivative liability(46,700)(57,600)
Non-cash interest on convertible notes73,33369,738
Accretion to redemption value on convertible notes15,84281,843
Changes in operating assets and liabilities:
Prepaid expenses and other current assets17,2772,720
Accounts payable(14,986)19,951
Accrued compensation785,7791,007,835
Accrued consulting34,333279,295
Accrued expenses and other56,955334,836
Net cash used in operating activities(497,467)(690,129)
Investing activities:
Proceeds from redemption of preferred stock of Holocom433,000343,000
Net cash provided by investing activities433,000343,000
Financing activities:
Proceeds from the issuance of convertible notes–341,632
Net cash provided by financing activities–341,632
Net change in cash and cash equivalents(64,467)(5,497)
Cash and cash equivalents, beginning of period220,645226,142
Cash and cash equivalents, end of period$156,178$220,645
Supplemental disclosure of cash flow information:
Cash paid for income taxes$2,400$2,400
Cash paid for interest$–$–
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.